AU2018244776B2 - Methods of treatment for kidney disease - Google Patents

Methods of treatment for kidney disease Download PDF

Info

Publication number
AU2018244776B2
AU2018244776B2 AU2018244776A AU2018244776A AU2018244776B2 AU 2018244776 B2 AU2018244776 B2 AU 2018244776B2 AU 2018244776 A AU2018244776 A AU 2018244776A AU 2018244776 A AU2018244776 A AU 2018244776A AU 2018244776 B2 AU2018244776 B2 AU 2018244776B2
Authority
AU
Australia
Prior art keywords
sdf
kidney
subject
kidney disease
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018244776A
Other languages
English (en)
Other versions
AU2018244776A1 (en
Inventor
James K. WILLIAMS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wake Forest University Health Sciences
Original Assignee
Wake Forest University Health Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wake Forest University Health Sciences filed Critical Wake Forest University Health Sciences
Publication of AU2018244776A1 publication Critical patent/AU2018244776A1/en
Application granted granted Critical
Publication of AU2018244776B2 publication Critical patent/AU2018244776B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2018244776A 2017-03-30 2018-03-29 Methods of treatment for kidney disease Active AU2018244776B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762478684P 2017-03-30 2017-03-30
US62/478,684 2017-03-30
PCT/US2018/025063 WO2018183625A1 (en) 2017-03-30 2018-03-29 Methods of treatment for kidney disease

Publications (2)

Publication Number Publication Date
AU2018244776A1 AU2018244776A1 (en) 2019-09-19
AU2018244776B2 true AU2018244776B2 (en) 2023-12-14

Family

ID=63678100

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018244776A Active AU2018244776B2 (en) 2017-03-30 2018-03-29 Methods of treatment for kidney disease

Country Status (6)

Country Link
US (2) US11229682B2 (https=)
EP (1) EP3600251A4 (https=)
JP (3) JP7667539B2 (https=)
AU (1) AU2018244776B2 (https=)
CA (1) CA3055761A1 (https=)
WO (1) WO2018183625A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018244776B2 (en) * 2017-03-30 2023-12-14 Wake Forest University Health Sciences Methods of treatment for kidney disease
WO2019032930A1 (en) 2017-08-11 2019-02-14 Wake Forest University Health Sciences USE OF CXCL12 FOR THERAPY AFTER SURGERY OF THE PROSTATE
KR102288446B1 (ko) * 2018-12-28 2021-08-10 서울대학교산학협력단 Cxcl12 검출용 제제를 포함하는 다낭신의 진단용 조성물 및 이의 이용

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100247491A1 (en) * 2007-02-01 2010-09-30 Christof Westenfelder Potentiation of Stem Cell Homing and Treatment of Organ Dysfunction or Organ Failure
US20110097379A1 (en) * 2008-05-09 2011-04-28 Wake Forest University Health Sciences Directed stem cell recruitment
US20160303197A1 (en) * 2013-12-13 2016-10-20 Mesoblast International Sarl Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2216630T3 (es) 1998-09-09 2004-10-16 Scios Inc Metodos de tratar la hipertension dependiente de la sal.
CA2412436C (en) 2000-06-05 2013-05-21 The Trustees Of Columbia University In The City Of New York Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
US7776564B2 (en) 2004-04-30 2010-08-17 Five Prime Therapeutics, Inc. Stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof and methods of use
US8492432B2 (en) 2005-08-17 2013-07-23 Hill's Pet Nutrition, Inc. Methods for the treatment of kidney disease
CN101595212B (zh) * 2006-10-12 2014-04-30 伊西康公司 肾源细胞及在组织修复和再生中的使用方法
JP2010523496A (ja) * 2007-03-30 2010-07-15 ザ クリーブランド クリニック ファウンデーション 虚血障害の治療方法
ATE543507T1 (de) 2007-11-07 2012-02-15 Ono Pharmaceutical Co Sdf-1 enthaltende zusammensetzung mit anhaltender freisetzung
WO2009114826A2 (en) 2008-03-13 2009-09-17 Angiodynamics, Inc. Treatment systems and methods for renal-related diseases
CA2772610C (en) 2009-08-28 2018-01-23 The Cleveland Clinic Foundation Sdf-1 delivery for treating ischemic tissue
AU2015256383B2 (en) 2014-05-08 2020-05-21 Wake Forest University Health Sciences Methods of treating incontinence and other sphincter deficiency disorders
KR102314110B1 (ko) 2014-09-16 2021-10-18 삼성디스플레이 주식회사 시각화 가속부를 포함하는 터치 표시 장치
AU2018244776B2 (en) * 2017-03-30 2023-12-14 Wake Forest University Health Sciences Methods of treatment for kidney disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100247491A1 (en) * 2007-02-01 2010-09-30 Christof Westenfelder Potentiation of Stem Cell Homing and Treatment of Organ Dysfunction or Organ Failure
US20110097379A1 (en) * 2008-05-09 2011-04-28 Wake Forest University Health Sciences Directed stem cell recruitment
US20160303197A1 (en) * 2013-12-13 2016-10-20 Mesoblast International Sarl Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
G. Stokman, et al.; "SDF-1 provides morphological and functional protection against renal ischaemia/reperfusion injury", Nephrology Dialysis Transplantation. 2010, 25(12): 3852-3859. DOI: 10.1093/ndt/gfq311. *

Also Published As

Publication number Publication date
JP2025069172A (ja) 2025-04-30
EP3600251A1 (en) 2020-02-05
JP2020512338A (ja) 2020-04-23
AU2018244776A1 (en) 2019-09-19
JP7667539B2 (ja) 2025-04-23
US20200093891A1 (en) 2020-03-26
US11229682B2 (en) 2022-01-25
JP2023015227A (ja) 2023-01-31
US20220105156A1 (en) 2022-04-07
EP3600251A4 (en) 2021-01-13
WO2018183625A1 (en) 2018-10-04
CA3055761A1 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
US20220105156A1 (en) Methods of treatment for kidney disease
US8883756B2 (en) SDF-1 delivery for treating ischemic tissue
US8828946B2 (en) Composition comprising interleukin-1 receptor antagonist and corticosteroid
TW201206463A (en) Methods and compositions for intrathecal delivery of Iduronate-2-sulfatase
EP3921029A1 (en) Periosteal skeletal stem cells in bone repair
US12514875B2 (en) Pharmaceutical composition comprising isolated mitochondria for preventing or treating tendinopathy
US10420818B2 (en) Methods of treating incontinence and other sphincter deficiency disorders
ES2654251T3 (es) Hormona paratiroidea (PTH) para su utilización en el tratamiento de la isquemia
KR20200013674A (ko) 허혈 조직을 치료하는 방법
US20240252548A1 (en) Adipose compositions and methods of use thereof
JP2008510709A (ja) ヒトｉｌ−１８を投与することによって創傷を治癒する方法
KR101144687B1 (ko) Ｇ－ｃｓｆ 를 함유하는 선유아세포 동원제 및 창상 치료제
ES2226326T3 (es) Hormona de crecimiento humana para estimular la hematopoyesis y la reconstitucion del sistema inmune despues del trasplante de celulas madre hematopoyeticas en seres humanos.
US20250295812A1 (en) Treatment for osteoarthritis
RU2694210C1 (ru) Препарат рекомбинантного интерферона-альфа собаки для применения в терапии природных вирусных инфекций собак
Roncalli et al. Biological approaches to ischemic tissue repair: gene-and cell-based strategies
CN112402454A (zh) 预激活间充质干细胞在治疗皮肤创伤的免疫生物学方面的应用
CN105264071B (zh) 用于治疗缺血组织的sdf-1递送
US20170049856A1 (en) Sdf-1 delivery for treating advanced ischemic cardiomyopathy
US20220257717A1 (en) Methods of Treatment Using Encapsulated Cells
CN118146318A (zh) 一种腺相关病毒衣壳蛋白及其用途
CN118222592A (zh) 编码vegfa和sdf-1的rna组合物及其应用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)